DK1147101T3 - Omvendt-hydroxamat-inhibitorer af matrix-metalloproteinaser - Google Patents
Omvendt-hydroxamat-inhibitorer af matrix-metalloproteinaserInfo
- Publication number
- DK1147101T3 DK1147101T3 DK00905758T DK00905758T DK1147101T3 DK 1147101 T3 DK1147101 T3 DK 1147101T3 DK 00905758 T DK00905758 T DK 00905758T DK 00905758 T DK00905758 T DK 00905758T DK 1147101 T3 DK1147101 T3 DK 1147101T3
- Authority
- DK
- Denmark
- Prior art keywords
- matrix metalloproteinases
- hydroxamate inhibitors
- reverse hydroxamate
- reverse
- inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/04—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
- C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
- C07D207/48—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D307/10—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/14—Radicals substituted by nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
- C07D317/14—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D317/28—Radicals substituted by nitrogen atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Furan Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23908799A | 1999-01-27 | 1999-01-27 | |
| PCT/US2000/002038 WO2000044739A1 (en) | 1999-01-27 | 2000-01-27 | Reverse hydroxamate inhibitors of matrix metalloproteinases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1147101T3 true DK1147101T3 (da) | 2003-03-10 |
Family
ID=22900549
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK00905758T DK1147101T3 (da) | 1999-01-27 | 2000-01-27 | Omvendt-hydroxamat-inhibitorer af matrix-metalloproteinaser |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US20020007060A1 (da) |
| EP (1) | EP1147101B1 (da) |
| JP (1) | JP4718686B2 (da) |
| KR (1) | KR100748010B1 (da) |
| CN (1) | CN1222519C (da) |
| AR (1) | AR029329A1 (da) |
| AT (1) | ATE228122T1 (da) |
| AU (1) | AU764383B2 (da) |
| BG (1) | BG105782A (da) |
| BR (1) | BR0007278A (da) |
| CA (1) | CA2358951C (da) |
| CO (1) | CO5150194A1 (da) |
| CZ (1) | CZ20012591A3 (da) |
| DE (1) | DE60000819T2 (da) |
| DK (1) | DK1147101T3 (da) |
| ES (1) | ES2187443T3 (da) |
| HK (1) | HK1043115A1 (da) |
| HU (1) | HUP0105477A2 (da) |
| IL (1) | IL143713A0 (da) |
| NO (1) | NO20013669L (da) |
| NZ (1) | NZ512372A (da) |
| PL (1) | PL349771A1 (da) |
| PT (1) | PT1147101E (da) |
| SK (1) | SK10582001A3 (da) |
| TR (1) | TR200102159T2 (da) |
| TW (1) | TWI225486B (da) |
| WO (1) | WO2000044739A1 (da) |
| ZA (1) | ZA200104979B (da) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9923078D0 (en) * | 1999-09-29 | 1999-12-01 | Phytopharm Plc | Sapogenin derivatives and their use |
| AU2001298065A1 (en) * | 2001-01-12 | 2003-09-02 | Abbott Laboratories | Process for the preparation of matrix metalloproteinase inhibitors |
| WO2003022801A1 (fr) | 2001-09-07 | 2003-03-20 | Kaken Pharmaceutical Co., Ltd. | Derives d'acide hydroxamique inverse |
| US7790767B2 (en) * | 2005-06-27 | 2010-09-07 | Nabriva Therapeutics Forschungs Gmbh | Pleuromutilin derivatives containing a hydroxyamino- or acyloxyaminocycloalkyl group |
| WO2009105140A2 (en) | 2007-12-11 | 2009-08-27 | Viamet Pharmaceuticals, Inc. | Metalloenzyme inhibitors using metal binding moieties in combination with targeting moieties |
| WO2015107139A1 (en) | 2014-01-17 | 2015-07-23 | Proyecto De Biomedicina Cima, S.L. | Compounds for use as antifibrinolytic agents |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK0780386T3 (da) * | 1995-12-20 | 2003-02-03 | Hoffmann La Roche | Matrixmetalloproteaseinhibitorer |
-
2000
- 2000-01-25 CO CO00003867A patent/CO5150194A1/es unknown
- 2000-01-26 AR ARP000100349A patent/AR029329A1/es not_active Application Discontinuation
- 2000-01-27 NZ NZ512372A patent/NZ512372A/xx unknown
- 2000-01-27 DK DK00905758T patent/DK1147101T3/da active
- 2000-01-27 IL IL14371300A patent/IL143713A0/xx unknown
- 2000-01-27 PT PT00905758T patent/PT1147101E/pt unknown
- 2000-01-27 SK SK1058-2001A patent/SK10582001A3/sk unknown
- 2000-01-27 PL PL00349771A patent/PL349771A1/xx not_active Application Discontinuation
- 2000-01-27 CZ CZ20012591A patent/CZ20012591A3/cs unknown
- 2000-01-27 BR BR0007278-8A patent/BR0007278A/pt not_active Application Discontinuation
- 2000-01-27 WO PCT/US2000/002038 patent/WO2000044739A1/en not_active Application Discontinuation
- 2000-01-27 HU HU0105477A patent/HUP0105477A2/hu unknown
- 2000-01-27 DE DE60000819T patent/DE60000819T2/de not_active Expired - Lifetime
- 2000-01-27 CN CNB008032378A patent/CN1222519C/zh not_active Expired - Fee Related
- 2000-01-27 CA CA002358951A patent/CA2358951C/en not_active Expired - Fee Related
- 2000-01-27 ES ES00905758T patent/ES2187443T3/es not_active Expired - Lifetime
- 2000-01-27 KR KR1020017009393A patent/KR100748010B1/ko not_active IP Right Cessation
- 2000-01-27 AT AT00905758T patent/ATE228122T1/de not_active IP Right Cessation
- 2000-01-27 AU AU27391/00A patent/AU764383B2/en not_active Ceased
- 2000-01-27 EP EP00905758A patent/EP1147101B1/en not_active Expired - Lifetime
- 2000-01-27 JP JP2000595995A patent/JP4718686B2/ja not_active Expired - Fee Related
- 2000-01-27 TR TR2001/02159T patent/TR200102159T2/xx unknown
- 2000-02-25 TW TW089101383A patent/TWI225486B/zh not_active IP Right Cessation
-
2001
- 2001-06-18 ZA ZA200104979A patent/ZA200104979B/en unknown
- 2001-07-16 US US09/905,242 patent/US20020007060A1/en not_active Abandoned
- 2001-07-26 NO NO20013669A patent/NO20013669L/no not_active Application Discontinuation
- 2001-08-03 BG BG105782A patent/BG105782A/xx unknown
-
2002
- 2002-04-18 HK HK02102947.8A patent/HK1043115A1/zh unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK0923585T3 (da) | Phosphinatbaserede inhibitorer af matrixmetalloproteinaser | |
| NO20034045L (no) | Metallproteinase-inhibitorer | |
| EE200300439A (et) | Metalloproteinaasi inhibiitorid | |
| ATE376999T1 (de) | Hydroxamate-derivate als deacetylase inhibitoren | |
| ATE524441T1 (de) | Vla-4-inhibitoren | |
| NO20034032L (no) | Metallproteinase-inhibitorer | |
| DE60002193D1 (de) | Metalloprotease inhibitoren | |
| DK1686113T3 (da) | Inhibitorer af aspartylprotease | |
| DK0938471T3 (da) | Fremstillingen og anvendelsen af ortho-sulfonamido-arylhydroxamsyrer som matrix-metalloproteinase- og TACE-inhibitorer | |
| DK1315694T3 (da) | Inhibitorer af alpha-4-medieret celleadhæsion | |
| DK1458447T3 (da) | Kombination af cytokrom-p450-beroende proteasinhibitorer | |
| DK1047450T3 (da) | Kombinationer af ACE-inhibitorer og MMP-inhibitorer | |
| DK1100792T3 (da) | Tricycliske sulfonamider og derivater deraf som inhibitorer af matrix-metalloproteinaser | |
| NO20014243L (no) | Dihetero-substituerte metalloproteaseinhibitorer | |
| EE200100611A (et) | NOS inhibiitorite uued farmatseutilised kombinatsioonid | |
| DE50115086D1 (de) | Lösungen von UV-vernetzbaren Polyacrylaten | |
| DK1147101T3 (da) | Omvendt-hydroxamat-inhibitorer af matrix-metalloproteinaser | |
| DE60009260D1 (de) | Thiopyranderivate as mmp-inhibitoren | |
| EE200100084A (xx) | NOS inhibiitorite uued farmatseutilised kasutusv�imalused | |
| SE0004239D0 (sv) | New use of an inhibitor | |
| DK1133486T3 (da) | Ikke-steroide hæmmere af betændelse |